141 related articles for article (PubMed ID: 6794908)
1. Effect of thymidine on the toxicity and antitumor activity of ftorafur.
Grossie VB; Loo TL
Cancer Treat Rep; 1981; 65(11-12):1087-91. PubMed ID: 6794908
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with cyclophosphamide and ftorafur against advanced L1210 murine leukemia.
Grossie VB; Rosenblum MG; Loo TL
Cancer Treat Rep; 1982 Aug; 66(8):1631-4. PubMed ID: 6809329
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
4. [Effect of cepharanthine on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207)--5-fluorouracil delivery into tumor tissue].
Ono M
Nihon Gan Chiryo Gakkai Shi; 1989 Jul; 24(7):1379-92. PubMed ID: 2509603
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
6. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
7. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
Cao S; Frank C; Shirasaka T; Rustum YM
Clin Cancer Res; 1995 Aug; 1(8):839-45. PubMed ID: 9816053
[TBL] [Abstract][Full Text] [Related]
8. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
9. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 5-fluorouracil and ftorafur. I. Quantitative and qualitative differences in toxicity to mice.
Johnson RK; Garibjanian BT; Houchens DP; Kline I; Gaston MR; Syrkin AB; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1335-45. PubMed ID: 797449
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the 3'-chloroethylnitrosourea analog of thymidine and the prevention by co-administered thymidine of lethality but not of anticancer activity.
Lin TS; Fischer PH; Marsh JC; Prusoff WH
Cancer Res; 1982 May; 42(5):1624-9. PubMed ID: 7066884
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of antitumor activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine in murine tumors.
Furusawa S; Mian AM
Cancer Treat Rep; 1987 May; 71(5):441-6. PubMed ID: 3567967
[TBL] [Abstract][Full Text] [Related]
13. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
14. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
15. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
Sirotnak FM; Moccio DM; Dorick DM
Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
[TBL] [Abstract][Full Text] [Related]
16. Effect of thymidine on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II).
Grossie VB; Valdivieso M; Drewinko B; Loo TL
Cancer Chemother Pharmacol; 1984; 13(1):27-30. PubMed ID: 6539657
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388.
Robak T; Szmigielska A
Neoplasma; 2000; 47(3):168-71. PubMed ID: 11043840
[TBL] [Abstract][Full Text] [Related]
19. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
[TBL] [Abstract][Full Text] [Related]
20. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
Chello PL; Sirotnak FM
Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
